公开(公告)号：US20140227305A1

公开(公告)日：2014-08-14

申请号：US13818711

申请日：2011-08-25

申请人： Romana Lange-Ruiss ,  Gilbert Reisbach ,  Wolfgang Hammerschmidt ,  Reinhard Zeidler

发明人： Romana Lange-Ruiss ,  Gilbert Reisbach ,  Wolfgang Hammerschmidt ,  Reinhard Zeidler

IPC分类号： A61K39/245

CPC分类号： A61K39/245 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/57 ,  A61K2039/575 ,  C07K14/005 ,  C07K2317/569 ,  C12N7/00 ,  C12N2710/16223 ,  C12N2710/16234 ,  C12N2710/16252 ,  C12N2710/16262 ,  C12N2710/16271

摘要： The present invention relates to a vaccine comprising a particle, said particle comprising (i) at least one Epstein-Barr virus (EBV) structural polypeptide, (ii) at least one EBV lytic polypeptide, (iii) membrane lipids, said particle being devoid of EBV DNA, wherein (a) the B-cell transformation capacity of one or more EBV polypeptides required for B-cell transformation as comprised in said particle is disabled while their immunogenicity is maintained; and/or (b) said particle is devoid of one or more EBV polypeptides required for B-cell transformation. Furthermore, the invention relates to a method for generating a particle, to a cell obtained in the method of the invention, a kit comprising the vaccine or the particle generated according to the method of the invention. Also, the invention relates to the use of the vaccine or the particle generated according to the method of the invention for generating CD8+ cells specific for an EBV antigen.

摘要翻译： 本发明涉及包含颗粒的疫苗，所述颗粒包含（i）至少一种爱泼斯坦 - 巴尔病毒（EBV）结构多肽，（ii）至少一种EBV溶解多肽，（iii）膜脂质，所述颗粒无缺陷 的EBV DNA，其中（a）包含在所述颗粒中的B细胞转化所需的一种或多种EBV多肽的B细胞转化能力在其免疫原性保持时被禁用; 和/或（b）所述颗粒缺乏B细胞转化所需的一种或多种EBV多肽。 此外，本发明涉及一种生成颗粒的方法，本发明方法获得的细胞包含根据本发明方法生成的疫苗或颗粒的试剂盒。 此外，本发明涉及根据本发明的方法产生的疫苗或颗粒用于产生对EBV抗原特异性的CD8 +细胞的用途。